Navigation Links
2 antibodies are better than 1
Date:2/7/2013

Cancer drugs of the new, molecular generation destroy malignant breast tumors in a targeted manner: They block characteristic molecules on tumor cells - receptors for the hormones estrogen or progesterone, or a co-receptor, called HER2, that binds to many growth factors. But about one in every six breast tumors has none of these receptors. Such cancers, called triple-negative, are particularly aggressive and notoriously difficult to treat.

Some of these therapy-resistant cancers have a potential molecular target for cancer drugs, a growth-factor receptor called EGFR, but an EGFR-blocking drug has proved ineffective in treating them. In a study published recently in the Proceedings of the National Academy of Sciences, Weizmann Institute researchers propose a potential solution: to simultaneously treat triple-negative breast cancer with two EGFR-blocking antibodies instead of one. In a study in mice, the scientists showed that a certain combination of two antibodies indeed prevented the growth and spread of triple-negative tumors. The research team, led by Prof. Yosef Yarden of the Biological Regulation Department and Prof. Michael Sela of the Immunology Department, included Drs. Daniela Ferraro, Nade`ge Gaborit, Ruth Maron, Hadas Cohen-Dvashi, Ziv Porat, Fresia Pareja, and Sara Lavi, Dr. Moshit Lindzen and Nir Ben-Chetrit.

Of the different combinations they tried, the scientists found that the approach worked when the two antibodies bound to different parts of the EGFR molecule. The combined action of the antibodies was stronger than would have been expected by simply adding up the separate effects of each. Apparently, the use of the two antibodies created an entirely new anti-cancer mechanism: In addition to blocking the EGFR and recruiting the help of immune cells, the antibodies probably overwhelmed the EGFR by their sheer weight, causing it to collapse inward from the membrane into the tumor cell.

Deprived of EGFR on its surface, the cells were no longer receiving the growth signals, preventing the growth of the tumor. This approach resembles the natural functioning of the immune system, which tends to block essential antigens at several sites by targeting them with multiple antibodies. If supported by further studies, the two-antibody approach, in combination with chemotherapy, might in the future be developed into an effective treatment for triple-negative breast cancer.


'/>"/>

Contact: Yivsam Azgad
news@weizmann.ac.il
972-893-43856
Weizmann Institute of Science
Source:Eurekalert

Related biology news :

1. Newly discovered breast milk antibodies help neutralize HIV
2. New methods for better purification of wastewater
3. Breakthroughs in Chikungunya research from A*STAR spell new hope for better treatment and protection
4. UNH researchers find African farmers need better climate change data to improve farming practices
5. Giant squids giant eyes: The better to see hungry whales with
6. Improved loblolly pines better for the environment, study finds
7. Fish larvae find the reef by orienting: The earlier the better
8. Intensive kidney dialysis indicates better survival rates than conventional dialysis
9. Modern hybrid corn makes better use of nitrogen, study shows
10. Bigger gorillas better at attracting mates and raising young
11. Better housing conditions for zebrafish could improve research results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/6/2017)... , Feb. 6, 2017 According to ... are driving border authorities to continue to embrace ... there are 2143 Automated Border Control (ABC) eGates ... deployed at more than 163 ports of entry ... to 2016 achieving a combined CAGR of 37%. ...
(Date:2/2/2017)... , Feb. 2, 2017  EyeLock LLC, a market ... new white paper " What You Should Know About ... of ensuring user authenticity is a growing concern. In ... of users. However, traditional authentication schemes such as username/password ... Biometric authentication offers an elegant solution to the ...
(Date:1/30/2017)... Jan. 30, 2017   Invitae Corporation (NYSE: ... genetic information companies, today announced that it will report ... provide 2017 guidance on Monday, February 13, 2017, and ... day at 4:45 p.m. Eastern / 1:45 p.m. Pacific. ... will briefly review financial results, guidance, and recent developments ...
Breaking Biology News(10 mins):
(Date:2/22/2017)... SAN DIEGO , Feb. 22, 2017 ... announced today expansion of its translational research program ... through establishment of laboratory facilities in San Diego.  ... San Diego BioLabs facility, a biotechnology incubator sponsored ... Sanofi. In November 2016, the Company ...
(Date:2/21/2017)... 21, 2017 /PRNewswire/ - SQI Diagnostics Inc. ("SQI" or the "Company") ... for the three months ended December 31, 2016. ... sciences and diagnostics company that develops and commercializes proprietary technologies ... ... on the commercial milestones achieved in fiscal 2016," said ...
(Date:2/21/2017)... Basel, Switzerland (PRWEB) , ... February 21, 2017 ... ... for biopharmaceutical and biotech research and development (R&D), today announced the establishment of ... headed by Managing Director Kevin Teburi, a recognized expert in life science informatics. ...
(Date:2/21/2017)... ... February 21, 2017 , ... With ... operational capacity with its strategic internal leadership to provide clients with best ... operational management. With office locations in North Carolina, Massachusetts, Ohio, Illinois, ...
Breaking Biology Technology: